NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 53.2% and is now trading at $17.88. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) posted its quarterly earnings results on Thursday, May, 7th. The company reported $0.33 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.77. The firm earned $22.38 million during the quarter, compared to the consensus estimate of $1.30 million. NextCure had a negative net margin of 65.22% and a negative return on equity of 7.12%. View NextCure's earnings history.

9 equities research analysts have issued 1 year target prices for NextCure's stock. Their forecasts range from $40.00 to $87.00. On average, they expect NextCure's share price to reach $64.67 in the next twelve months. This suggests a possible upside of 261.7% from the stock's current price. View analysts' price targets for NextCure.

Media coverage about NXTC stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NextCure earned a news impact score of -3.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about NextCure.

NextCure saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,740,000 shares, an increase of 41.5% from the June 15th total of 1,230,000 shares. Based on an average trading volume of 301,900 shares, the days-to-cover ratio is presently 5.8 days. Currently, 10.7% of the company's shares are sold short. View NextCure's Current Options Chain.

Some companies that are related to NextCure include Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Xencor (XNCR), I-Mab (IMAB), Aurinia Pharmaceuticals (AUPH), Intra-Cellular Therapies (ITCI), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Ironwood Pharmaceuticals (IRWD), Akebia Therapeutics (AKBA) and Epizyme (EPZM). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $17.88.

NextCure has a market capitalization of $492.06 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]